Available Brands
Did you find this information helpful?
Author Details
Written By
Prakruthi Madhusudan
MSc Bioinformatics

Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 12 Nov 2026 | 04:45 PM (IST)

Want to know more?
Read Our Editorial Policy
Quick Summary
LENVATINIB
Last updated on 12 Nov 2026 | 04:45 PM (IST)
LENVATINIB
Molecule Overview
Lenvatinib is an oral targeted medicine that blocks several growth-signal receptors involved in tumour blood vessel formation and cancer cell growth. It belongs to a class of medicines called multi-kinase inhibitors, used across thyroid, kidney, liver, and endometrial cancers. It is a prescription-only medicine.
Medical Classification
Therapeutic Class: Anti-cancer (oncology) targeted therapy.
Pharmacological Class: Multi-receptor tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR, RET, KIT).
Drug Family: Small-molecule antiangiogenic kinase inhibitors.
ATC Classification: L01EK01 (Lenvatinib).
Conditions Treated
Approved: Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC); advanced renal cell carcinoma (RCC), combined with pembrolizumab as first-line treatment or with everolimus after prior anti-angiogenic therapy; unresectable hepatocellular carcinoma (HCC) as first-line treatment; and advanced endometrial carcinoma, combined with pembrolizumab, in specific biomarker-defined patients after disease progression on prior therapy.
Commonly used for: Patients with these specific advanced cancer types, generally after disease has progressed or is no longer suitable for other primary treatments like radioactive iodine or surgery.
Off-label use (only under medical guidance): Being studied in other solid tumours in clinical trials; not routine outside its approved indications.
Available Strengths & Dosage Forms
Oral capsules: 4 mg and 10 mg (also available as pre-packaged daily-dose combinations for 8 mg, 12 mg, 14 mg, 18 mg, 20 mg, and 24 mg total daily doses).
How the Molecule Works
Lenvatinib blocks multiple receptors — including VEGFR (vascular endothelial growth factor receptor), FGFR, PDGFR, RET, and KIT — that tumours rely on to form new blood vessels (angiogenesis) and to send growth signals. By blocking these pathways, lenvatinib helps starve tumours of their blood supply and slows cancer cell proliferation.
Dosage & Administration
Standard dose (DTC): 24 mg orally once daily, continued until disease progression or unacceptable toxicity.
Condition-wise dose (HCC, monotherapy): Weight-based: 12 mg once daily for patients 60 kg or more, or 8 mg once daily for patients under 60 kg.
Condition-wise dose (RCC or endometrial carcinoma, combined with pembrolizumab or everolimus): Dosing varies by combination and indication (commonly 20 mg once daily with pembrolizumab for RCC/endometrial carcinoma, or 18 mg once daily with everolimus for RCC) — refer to the specific combination regimen and the partner drug's prescribing information.
Route: Oral, once daily, at approximately the same time each day, with or without food.
Missed dose: If a dose is missed and it's not remembered within 12 hours of the scheduled time, skip it and take the next dose at the regular scheduled time.
Overdose: May worsen known side effects such as high blood pressure or bleeding; requires urgent medical attention.
Side Effects
Common: High blood pressure, fatigue, diarrhoea, decreased appetite, weight loss, nausea, mouth sores (stomatitis), and hand-foot skin reactions.
Serious: Cardiac dysfunction (heart failure), arterial blood clot events (heart attack, stroke), liver failure, kidney failure or impairment, gastrointestinal perforation or fistula formation, QT interval prolongation, bleeding events (including rare fatal hemorrhages, particularly in anaplastic thyroid cancer), and impaired wound healing.
Emergency symptoms: Chest pain, sudden weakness or slurred speech, severe abdominal pain, yellowing of the skin/eyes, significant bleeding, or a marked drop in urine output.
Recovery advice: High blood pressure is very common and usually managed with blood-pressure medicines rather than stopping treatment; regular monitoring allows the many possible serious effects to be caught and managed early through dose adjustment or interruption.
Warnings & Precautions
Pregnancy: Can cause fetal harm; effective contraception is required during treatment and for a period after stopping.
Breastfeeding: Not recommended during treatment and for a period after the last dose.
Liver disease: Dose reduction needed in severe impairment (Child-Pugh C) for DTC dosing; used with caution and monitoring across indications.
Kidney disease: Dose reduction needed in severe impairment for DTC and RCC dosing; used with caution and monitoring.
Elderly: Used with routine monitoring; may have increased sensitivity to certain side effects.
Children: Not established for use in children; a medicine for adult cancer patients.
Drug Interactions
Strong CYP3A4 and P-glycoprotein inhibitors/inducers: can alter lenvatinib levels; used with caution and monitoring.
Other blood-pressure-lowering medicines: often needed alongside lenvatinib to manage the high blood pressure it commonly causes, rather than a concern to avoid.
Other QT-prolonging medicines: increases the risk of heart rhythm effects when combined.
Everolimus or pembrolizumab (specific combination regimens): used together at adjusted, protocol-specific doses as part of approved combination therapy, not a general interaction to avoid.
Monitoring Requirements
Blood pressure checks, particularly during the first two months and periodically thereafter.
Liver and kidney function tests periodically.
Thyroid function (TSH) monitoring, given the effect on thyroid hormone suppression in DTC patients.
ECG and electrolyte monitoring in patients at risk of QT prolongation; cardiac function assessment periodically.
Alternative Molecules
Sorafenib, Cabozantinib (other multi-kinase inhibitors used in overlapping indications); Sunitinib, Pazopanib (other antiangiogenic kinase inhibitors, mainly RCC).
Combination Therapies
Used as monotherapy for DTC and first-line HCC; combined with pembrolizumab for RCC and endometrial carcinoma, and combined with everolimus for RCC after prior anti-angiogenic therapy.
Thyroid Cancer Medicines
Kidney & Liver Cancer Medicines
Multi-Kinase Inhibitors
FAQs
Q1.
It's used to treat certain advanced thyroid, kidney, liver, and endometrial cancers, either alone or in combination with other targeted or immune therapies.
Q2.
Because its blood-vessel-blocking (antiangiogenic) mechanism affects normal blood vessel function too, high blood pressure is one of the most common effects and is usually managed with blood-pressure medicines.
Q3.
It depends on the cancer type — it's used alone for thyroid cancer and first-line liver cancer, but combined with pembrolizumab or everolimus for kidney and endometrial cancers.
Q4.
It carries risks of heart problems, blood clots, liver and kidney issues, bleeding, and gastrointestinal perforation, among others, which is why regular monitoring throughout treatment is important.
Q5.
Generally until the disease progresses or side effects become unacceptable, as decided by the treating oncologist.
References
Disclaimer
The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your oncologist to know if this treatment is appropriate for your condition.






